Effects of cytokine signaling inhibition on inflammation-driven tissue remodeling


Fibrosis is a common condition that can affect all body tissues, driven by unresolved tissue inflammation and resulting in tissue dysfunction and organ failure that could ultimately lead to death. A myriad of factors are thought to contribute to fibrosis and, although it is relatively common, treatments focusing on reversing fibrosis are few and far between. The process of fibrosis involves a variety of cell types, including epithelial, endothelial, and mesenchymal cells, as well as immune cells, which have been shown to produce pro-fibrotic cytokines. Advances in our understanding of the molecular mechanisms of inflammation-driven tissue fibrosis and scar formation have led to the development of targeted therapeutics aiming to prevent, delay, or even reverse tissue fibrosis. In this review, we describe promising targets and agents in development, with a specific focus on cytokines that have been well-described to play a role in fibrosis: IL-1, TNF-α, IL-6, and TGF-β. An array of small molecule inhibitors, natural compounds, and biologics have been assessed in vivo, in vivo, and in the clinic, demonstrating the capacity to either directly interfere with pro-fibrotic pathways or to block intracellular enzymes that control fibrosis-related signaling pathways. Targeting pro-fibrotic cytokines, potentially via a multi-pronged approach, holds promise for the treatment of inflammation-driven fibrotic diseases in numerous organs. Despite the complexity of the interplay of cytokines in fibrotic tissues, the breadth of the currently ongoing research targeting cytokines suggests that these may hold the key to mitigating tissue fibrosis and reducing organ damage in the future.

Publication DOI: https://doi.org/10.1016/j.crphar.2021.100023
Divisions: College of Health & Life Sciences > School of Biosciences
College of Health & Life Sciences
Additional Information: © 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Current Research in Pharmacology and Drug Discovery 2 (2021) 100023
Uncontrolled Keywords: IL-1,TGF-β,TNF-α,Fibrosis,Cytokine,Inhibition,IL-6
Publication ISSN: 2590-2571
Last Modified: 15 May 2024 07:17
Date Deposited: 04 Jan 2022 12:52
Full Text Link:
Related URLs: https://www.sci ... via%3Dihub#sec7 (Publisher URL)
PURE Output Type: Article
Published Date: 2021-04-10
Accepted Date: 2021-03-23
Submitted Date: 2020-12-31
Authors: Bignold, Rebecca (ORCID Profile 0000-0002-6172-418X)
Johnson, Jill R (ORCID Profile 0000-0002-5149-0084)



Version: Published Version

License: Creative Commons Attribution

| Preview

Export / Share Citation


Additional statistics for this record